The absence of HLA class II 
Introduction
Type H bare lymphocyte syndrome (BLS),' or HLA class 11- deficient combined immunodeficiency, is an autosomal recessive disorder in which the HLA class II structural genes are not transcribed in any tissue either constitutively or in response to inducing stimuli (1, 2) . The resulting absence of class H histocompatibility antigen expression on antigen-presenting cells, such as B lymphocytes and cells of the macrophage lin- eage, significantly impairs cellular and humoral immune responses (reviewed in reference 3). Thus, BLS immunodeficiency is characterized by a paucity of T lymphocyte responses and impaired antibody production upon challenge with foreign antigens, leading to extreme susceptibility to viral, bacterial, and fungal infections. These pathophysiologic defects in BLS have been directly attributed to a lack of HLA class H-restricted antigen presentation to T lymphocytes.
The absence of HLA class H gene expression results from mutations in transactivator genes necessary to mediate transcription of the coordinately regulated class H genes (2, 4, 5) . Genetic studies have revealed that at least four distinct molecular defects manifest as the class II null phenotype of BLS patient cells (6, 7) . We have previously demonstrated that a BLS cell line (BLS-1 ) isolated from a patient from one of these complementation groups, following transfection with wild-type class H genes, has defects in class 11-mediated presentation of native exogenous antigens and structurally altered class H af3 molecules (8) . This finding suggested that the molecular pathways regulating HLA class H structural gene expression and those modulating pathways of class II functional antigen processing and presentation share common elements, possibly coregulated by the transcriptionally active elements missing in patients with BLS.
Presentation of exogenous foreign antigens by antigen-presenting cells (APC) is a complex process, in which antigens are proteolytically processed to peptide epitopes that are then bound by class H molecules and displayed at the cell surface for recognition by antigen-specific CD4+ helper T lymphocytes (reviewed in reference 9). Mutational analyses have shown that genes essential for appropriate class 11-mediated antigen presentation, recently identified as HLA-DMA and -DMB (10, 11) , map within the class HI region of the MHC (12) (13) (14) (15) , raising the possibility that this clustering of genes encoding both class H structural proteins and accessory molecules required for their antigen-presenting function would ensure their coordinate regulation. In addition, there may be multiple genes outside the MHC that are required for optimal antigen presentation, such as the invariant chain ( 16) Lymphocyte Syndrome and are members of complementation groups I, II, and IV, respectively (7). The class II-null B-LCL 6.1.6 was generated after in vitro mutagenesis (19) . 6.1.6 (classified as complementation group III [7] ) has a mutation resulting in the absence of class II transcription and thus exhibits the class II null phenotype of BLS patient cells. T2 (.174 x CEM.T2) is a human cell hybrid that lacks all four copies of the MHC class II region on chromosome 6 (20) . Class II DRa (DRAl) and DR,/ (DRB 1*0401) cDNA encoding DR4w4 molecules were introduced into SJO and 6.1.6 using retrovirus-mediated gene transfer (21) . The BLS-l.DR4w4, BLS-1.DR3, BLS-L.DR5, and T2.DR4w4 transferent cells have been described (8 Primer-directed amplification of cDNA was accomplished using PCR. 5' and 3' primers for amplification of DMA cDNA were: 5 '-ACiTITI'-CCCAGAACACTCGG and S '-CTGGAAGCTGAGTCCATCG and the expected product is 340 bp. 5' and 3' primers for amplification of DMB cDNA were: 5 '-ACAGCACCTCAACCAAAAAGA and 5 '-GGGGTT-AAGGCTAAATGGGA and the expected product is 320 bp. DMA and DMB cDNA were amplified for 30 cycles (denaturation for 1 min at 930C, annealing for 1 min at 550C and polymerization for 1 min at 720C). The reaction products were visualized by agarose gel electrophoresis and staining with ethidium bromide. PCR products were sized using a 1-kb DNA ladder (GIBCO BRL, Gaithersburg, MD). The identity of the putative DMA band amplified in BLS-l was confirmed by DNA sequence analysis. The presence of intact cDNA in samples derived from cellular RNA was confirmed by the presence of a product amplified using primers specific for the actin gene. A higher molecular weight band amplified in some of the RNA samples is likely to be resulting from genomic DNA contamination of the RNA sample, since the size of the product (-1 kb for DMA and -1.5 kb for DMB) corresponds to the size of the product directly amplified from genomic DNA of Vavy. Cell fusions. Fusions between BLS-l (DR3,5) and .174 or between SJO (DR5,7) and .174 were accomplished using 50% polyethylene glycol-1500, 5% DMSO (4). Before cell hybridization, genes encoding drug resistance were' introduced into the cell lines as follows: BLS-1, hygromycin-resistance gene; .174, neomycin-resistance or gpt genes; and SJO, neomycin-resistance gene linked to a DRB1 *0401 gene. The BLS-l x .174 (neo) fused cells were selected using hygromycin B (Calbiochem Novabiochem, La Jolla, CA) (150 pg/ml) and G418
(GIBCO BRL) (1 mg/ml). The SJO x .174 (gpt) fused cells were selected for using G418 and mycophenolic acid (10 pg/ml) plus xanthine (6 Ag/ml) (Sigma Immunochemicals, St. Louis, MO). Stable independently fused drug-resistant populations were analyzed. The BLS-1 x SJO hybrids have been described (8) .
Analyses of HLA class II dimers using immunoblotting. Cells were lysed at 5 x 107/ml in 1% NP-40, 0.15M NaCl, 5mM EDTA, 50mM
Tris-Cl, pH 7.2, 1.0 mM PMSF, 1.0 ag/ml leupeptin, and 1.0 /Lg/ml pepstatin for 30 min on ice; protease inhibitors were obtained from Boehringer Mannheim Corp. (Indianapolis, IN). To detect HLA-DR af dimers, 50 ,Ig of total cell lysate was mixed with the appropriate volume of 4x nonreducing SDS sample buffer (l x concentration: 62.5 mM Tris-Cl, pH 6.8, 0.2% SDS, 10% glycerol) and incubated for 30 min at room temperature. To detect HLA-DRP3 monomers, 25 ,ug of total cell lysate was mixed with an appropriate volume of 4x reducing SDS sample buffer (lx concentration as above plus 100 mM DTT) and boiled for 10 min. Samples were electrophoresed on a 10% SDSpolyacrylamide gel and subsequently transferred to nitrocellulose. Immunoblotting was accomplished using hybridoma supernatant containing mAbs L243 (23) or XD5.Al 1 (27) . Binding of primary mAbs was detected using peroxidase-conjugated F(ab ' )2 goat anti-mouse IgG + IgM (Jackson ImmunoResearch Laboratories) and a chemiluminescent substrate for peroxidase, ECL, (Amersham Corp., Arlington Heights, IL) followed by exposure to film.
Results
HLA-DR transfected BLS cells exhibit conformationally altered class II dimers. Defects in class II antigen structure have been linked with the impaired ability of both in vitro-generated ( 11, 13, 14, 28) and naturally occurring (BLS-1) (8) mutant cells to present peptides derived from exogenously supplied antigens. Previously we showed that BLS-1 cells expressing introduced DR4w4 and DR3 molecules failed to bind allele-specific anti-DR3 and -DR4w4 mAbs that recognize conformation-dependent epitopes on these DR molecules (8) . These conformation-dependent epitopes apparently reflect the specificity of selected antibodies to recognize intact peptide/class TI complexes. Structurally altered peptide/class II complexes also show a marked reduction in ability to remain stable DR a,/ heterodimers after room temperature incubation in low concentrations of SDS (14, 28 were transferred into cells representative of two additional BLS complementation groups, 6.1.6 and SJO. We then investigated whether DR a/3 heterodimers with different allelic specificities, expressed in distinct BLS cells, would also exhibit this SDS instability. Aliquots of total cell lysate were incubated in either nonreducing SDS sample buffer at room temperature or boiled in reducing SDS sample buffer before SDS-PAGE and transfer to nitrocellulose. Immunoblotting was performed on the nonreduced samples using mAb L243 (Fig: 1, top) which recognizes mature DR heterodimers, and on the reduced samples using mAb XD5.A1 1 (Fig. 1, bottom (14, 28) . DR3 molecules in the mutant cells are preferentially loaded with a nested set of invariant chain-derived peptides (CLIP) that do not impart dimer stability in SDS (29, 30) . Interestingly, consistent with our observation, HPLC analyses of peptides eluted from DR4w4 and DR5 molecules purified from the in vitro-generated mutant APC T2.DR4w4 and T2.DR5 revealed a minor proportion of peptides that were distinguishable from CLIP peptides and were not present in DR3 molecules purified from T2 cells (31) . CLIP binds promiscuously to many class II alleles; however, its avidity for DR4w4 and DR5 molecules is reduced compared with DR3 antigens (3 1 (Fig. 2) . Upon incubation with a preparation of proteolyzed TT (containing antigenic peptides), BLSl.DR4w4, 6.1.6.DR4w4, and SJO.DR4w4 cells were able to stimulate lymphokine production by a murine T cell hybridoma that is specific for TT in the context of DR4w4 (Fig. 2 A) . The ability of mutant BLS cells to present tetanus peptides was comparable to that of the wild-type DR4w4 B-LCL Priess; the presence of antigenic peptides in the proteolyzed tetanus was confirmed by incubation of the preparation with chemicallyfixed Priess cells (data not shown). In contrast, BLS-l.DR4w4, SJO.DR4w4, and 6.1.6.DR4w4 cells showed a marked reduction in ability to present peptide epitopes derived from native TT to this T cell hybridoma (Fig. 2 A) .
Similarly, after incubation with formalin-fixed influenza virus, the three DR-transfected BLS cells (BLS-1, SJO, and 6.1.6) were each deficient in presenting native HA to a T cell hybridoma recognizing DR4w4/HA307-319 complexes (Fig. 2 B) .
The HA peptide 307-319 was presented with comparable efficiency by the mutant BLS and wild-type Priess cells. The small amount of T cell stimulation observed after incubation of 6.1.6.DR4w4 cells with native TT (Fig. 2 A) was not observed after incubation of these cells with influenza virus, suggesting that the severity of the APC deficiency may be related to the nature of the protein antigen being processed and presented. Thus, cells representative of three distinct BLS complementation groups were deficient in the class 11-mediated presentation of the native exogenous antigens, TI and influenza HA, although presentation of preprocessed antigenic peptides by these (Fig. 2) . BLS cells lack HLA-DM mRNA. The defects in class IImediated antigen presentation in BLS cells are similar to those observed in the in vitro-generated mutant cell lines 9.5.3 (28), 2.2.93 (11), 721.174 (13) , and T2 (14) . These mutants each lack or have mutations in MHC-linked genes required for presentation of native class II-restricted antigens, recently identified as the DMA and DMB genes (10, 11) . The DM genes map in the class II region of the MHC and contain 5' regulatory sequences that are similar to the promoter regions of the DR, DQ, and DP structural genes (12) . Because the mutations in BLS cells are in trans-acting factors required for transcription of the class II structural genes, we hypothesized that BLS cells would also be deficient in expression of DM genes. Indeed, in a previous study, the SJO cell line from BLS group IV had been examined for DM mRNA, with evidence suggesting these cells are unable to produce both DMA and DMB (32) .
A PCR assay was used to detect DMA and DMB mRNA in cells representative of the four BLS complementation groups, BLS-1, BLS-2, 6.1.6, and SJO (Fig. 3) . The amount of PCRamplified signal corresponding to the expected DMA and DMB products in each BLS cell was compared to that of a wild-type B cell line Vavy and the DM-deletion mutant T2. All four BLS cells were deficient in DMB mRNA (Fig. 3, bottom) . In contrast, assays of BLS-1, BLS-2, and 6.1.6 showed a weak band corresponding to DMA mRNA, while SJO lacked this band (Fig. 3, top) . The identity of the putative DMA band in BLS-1 cells was confirmed by DNA sequencing of the PCR product. The difference in intensity of DMA bands between wild-type B cells and these BLS cells suggests that BLS cells contain reduced amounts of steady-state DMA mRNA. This observation is consistent with the report that BLS-1 cells also contain reduced but detectable amounts of DQA1 mRNA (17) . These data indicate that the trans-acting factors missing in each of the four BLS cells, representing all four BLS complementation groups, are required for transcriptional activation of both the DMA and DMB genes, although DMA expression is apparently regulated by additional parameters.
Fusion (Table I) and by mAb SFR3-DR5 (33) that recognizes DR5 molecules (data not shown). The SJO cells also contained a transgene encoding DR4w4p chains; however, surface expression of DR4w4 molecules was only observed after transcriptional activation of endogenous DR alpha chain expression in the hybrid cells (Table  I and data not shown).
The DR af3 structure in these hybrid cells, as well as the previously characterized BLS-1 x SJO hybrid cells (8) , was investigated using the assay for class II dimer stability described above. Upon fusion of BLS-1 or SJO cells with each other or with 721.174, the amount of SDS-stable dimer corresponding to the endogenous DR gene products was present in wild-type amounts (Fig. 1, top) . The structure of endogenously expressed DR3 molecules in the BLS-1 X .174 fused cells was also investigated using the conformationally-sensitive anti-DR3 mAb 16.23. Fusion of BLS-1 with .174 resulted in production of DR3 molecules containing the mAb 16.23 epitope; the amount of mAb 16.23 bound was significantly greater than that bound to BLS-1.DR3 transferents and comparable to the wild-type DR3 B cell line Mat (Table I) . Identical results were previously obtained after fusion of BLS-1 and SJO (8) . Taken together, these data indicate that fusion with 721.174 results in the production of DR molecules that have the same conserved structural features as DR molecules present in wild-type B cells, a phenotype that is markedly distinct from DR molecules in BLS and mutant APC such as 721.174. These results are simply explained if the trans-acting factors that mediate class H structural gene transcription also mediate transcription of genes required for a functional APC phenotype.
Presentation of exogenous native antigen was also restored in SJO x .174 hybrid cells (Fig. 4) . In marked contrast to SJO.DR4w4 cells, the SJO X .174 cells were able to present native TT (Fig. 4 A) or native HA (Fig. 4 B) to the appropriate DR4w4-restricted murine T cell hybridomas. While the presentation of HA peptides, either preprocessed or derived after celluAm. (Fig. 3) The genetic defects in three of the BLS complementation groups are known; each involves defective transcription factors required for coordinate expression of HLA class II genes. The transcription factor defective in cells of complementation groups I and IV, such as BLS-1 and SJO, is apparently RFX, since purified RFX protein complements DRA transcription in these cells (36) . An RFX heterodimer most likely interacts with consensus X box elements present in HLA class II upstream regulatory regions (36) . A deficiency in an X box binding protein in the 6.1.6 cell line, complementation group III, has also been reported (37) . The defective APC phenotype manifested in each of these three distinct complementation groups suggests that genes required for antigen presentation are coregulated by the same set of transactivators as the class II structural genes. Cells in BLS complementation group II, such as BLS-2, are defective in the CIITA protein (38) , a protein that may not directly bind DNA (38) but which likely acts in both constitutive and y-interferon-stimulated class II transcriptional activation (39, 40 (12) ; and like the class II structural and invariant chain genes, the DM genes are likely to be coordinately upregulated in response to y-IFN (43) . The presence of these similar regulatory elements supports the interpretation that each of the transcription factors defective in the BLS complementation groups also act on the promoter elements for the DMA and DMB genes, and in this way, function as a coordinate regulator of the separate pathways of structural class II gene expression and functional antigen processing and presentation. However, the transcription factors absent in the BLS cells may be involved in regulation of additional genes required for optimal antigen processing and presentation. Accordingly, we have observed a decrease in amounts of intracellular invariant chain in each of the four BLS cells described here (S. Kovats and J. S. Blum, unpublished observations), consistent with coregulation of invariant chain gene transcription via 5' X and Y box consensus elements (16) .
The conservation of shared transcriptional regulatory elements provides a simple and effective mechanism for coregulation of these two distinct pathways, and is thus an interesting genetic model for the coevolution of distinct genes whose products participate in different aspects of a common intracellular process. As the class II a/3 dimer stability experiments demonstrate, products of genes involved in APC function appear to directly interface with the products of the class II structural genes themselves to produce fully competent APC. Furthermore, both the structural class II pathway and the antigen processing/presentation pathway likely contribute to the clinical immunodeficiency associated with BLS, implying that therapies directed at the coordinate regulatory elements rather than the class II genes themselves are needed to fully correct the functional deficits.
